Article
Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.
Blood - 29 Oct 2015
Guièze Romain, Robbe Pauline, Clifford Ruth, de Guibert Sophie, Pereira Bruno, Timbs Adele, Dilhuydy Marie-Sarah, Cabes Maite, Ysebaert Loïc, Burns Adam, Nguyen-Khac Florence, Davi Frédéric, Véronèse Lauren, Combes Patricia, Le Garff-Tavernier Magali, Leblond Véronique, Merle-Béral Hélène, Alsolami Reem, Hamblin Angela, Mason Joanne, Pettitt Andrew, Hillmen Peter, Taylor Jenny, Knight Samantha J L, Tournilhac Olivier, Schuh Anna
Abstract excerpt
Although TP53, NOTCH1, and SF3B1 mutations may impair prognosis of patients with chronic lymphocytic leukemia (CLL) receiving frontline therapy, the impact of these mutations or any other, alone or in combination, remains unclear at relapse. The genome of 114 relapsed/refractory patients included in prospective trials was screened using targeted next-generation sequencing of the TP53, SF3B1, ATM, NOTCH1, XPO1,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.